Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 8/2002

01-10-2002 | Original Article

Large-scale expansion of CD3+CD56+ lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants

Authors: A. Gritzapis, D. Dimitroulopoulos, E. Paraskevas, C. Baxevanis, M. Papamichail

Published in: Cancer Immunology, Immunotherapy | Issue 8/2002

Login to get access
Metadata
Title
Large-scale expansion of CD3+CD56+ lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants
Authors
A. Gritzapis
D. Dimitroulopoulos
E. Paraskevas
C. Baxevanis
M. Papamichail
Publication date
01-10-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 8/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0298-y

Other articles of this Issue 8/2002

Cancer Immunology, Immunotherapy 8/2002 Go to the issue

Original Article

Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer

Original Article

Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model

Perspectives

Antitumor vaccines: is it possible to prevent a tumor?

Original Article

Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response

Original Article

Comparison of the TCR ζ-chain with the FcR γ-chain in chimeric TCR constructs for T cell activation and apoptosis

Original Article

Influence of adenoviral vector on expression of angiogenesis regulating factors in non-small cell lung cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits